CR20140514A - Proceso preparativo - Google Patents

Proceso preparativo

Info

Publication number
CR20140514A
CR20140514A CR20140514A CR20140514A CR20140514A CR 20140514 A CR20140514 A CR 20140514A CR 20140514 A CR20140514 A CR 20140514A CR 20140514 A CR20140514 A CR 20140514A CR 20140514 A CR20140514 A CR 20140514A
Authority
CR
Costa Rica
Prior art keywords
morpholin
triazol
pyrimidin
pyrazol
preparation process
Prior art date
Application number
CR20140514A
Other languages
English (en)
Inventor
Hans-Christian Militzer
Johannes Eggert
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48325714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140514(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CR20140514A publication Critical patent/CR20140514A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Abstract

La presente invención se refiere aun proceso para la preparación de1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1H-1,2,3-triazol-1-il)-1H-pirazol-5-ol (I - forma enol) o de 2-[6-(morfolin-4-il)pirimidin-4-il]-4- (1H-1,2,3-triazol-1-il)-1,2-dihidro-3H-pirazol-3-ona (I - forma ceto) y de 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1H-1,2,3-triazol-1-il)-1H-pirazol-5-olato de sodio (II) a partir de 1,2,3-triazol (III), de bromoacetato de metilo (IV-Me-Br) o de bromoacetato de etilo (IV-Et-Br), de 4,6-dicloropirimidina (VIII), de morfolina (IX) y dehidracina (XII).
CR20140514A 2012-05-08 2014-11-07 Proceso preparativo CR20140514A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167152 2012-05-08
PCT/EP2013/059418 WO2013167552A1 (de) 2012-05-08 2013-05-06 Verfahren zur herstellung von triazol-verbindungen

Publications (1)

Publication Number Publication Date
CR20140514A true CR20140514A (es) 2014-12-02

Family

ID=48325714

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140514A CR20140514A (es) 2012-05-08 2014-11-07 Proceso preparativo

Country Status (36)

Country Link
US (1) US10301289B2 (es)
EP (1) EP2847183B1 (es)
JP (1) JP6149104B2 (es)
KR (1) KR102086389B1 (es)
CN (1) CN104411704B (es)
AP (1) AP2014008089A0 (es)
AU (1) AU2013258107B2 (es)
BR (1) BR112014027564B1 (es)
CA (1) CA2872726C (es)
CL (2) CL2014003003A1 (es)
CO (1) CO7121324A2 (es)
CR (1) CR20140514A (es)
CU (1) CU20140128A7 (es)
DK (1) DK2847183T3 (es)
DO (1) DOP2014000254A (es)
EA (1) EA027804B1 (es)
ES (1) ES2641205T3 (es)
HK (1) HK1208027A1 (es)
HR (1) HRP20171321T1 (es)
HU (1) HUE034430T2 (es)
IL (1) IL235441A (es)
LT (1) LT2847183T (es)
MX (1) MX350519B (es)
MY (1) MY184577A (es)
NZ (1) NZ701661A (es)
PE (1) PE20142453A1 (es)
PH (1) PH12014502482A1 (es)
PL (1) PL2847183T3 (es)
PT (1) PT2847183T (es)
RS (1) RS56255B1 (es)
SG (2) SG10201609319YA (es)
SI (1) SI2847183T1 (es)
TN (1) TN2014000469A1 (es)
UA (1) UA116349C2 (es)
WO (1) WO2013167552A1 (es)
ZA (1) ZA201408571B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37222A (es) * 2016-05-03 2017-11-30 Bayer Pharma AG PROCEDIMIENTO PARA LA PREPARACIÓN DE DERIVADOS DE 1-FENILO-1,2,4-TRIAZOL SUSTITUIDOS POR 5-HIdroxIalQUILO
CN108084099B (zh) * 2017-12-20 2019-01-29 天驰药业有限公司 一种1,2,3-三氮唑化合物的合成方法
US10702525B1 (en) 2019-09-04 2020-07-07 United Arab Emirates University Pyrimidine derivatives as anti-diabetic agents
EP3888684A1 (en) 2020-03-31 2021-10-06 Bayer Animal Health GmbH Composition having improved voluntary acceptance
CN114264752B (zh) * 2021-12-29 2023-08-15 北京金城泰尔制药有限公司 溴乙酸甲酯的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK135184A (da) 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
US4752910A (en) 1984-10-30 1988-06-21 Prime Computer, Inc. Method and apparatus for continuous after-imaging
UY27813A1 (es) 2002-05-31 2003-12-31 Smithkline Beecham Corp Inhibidores de la peptido-desformilasa
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
WO2005044785A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
DE102008020113A1 (de) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
EP1877399A1 (en) 2005-04-26 2008-01-16 Pfizer Limited Triazole derivatives as vasopressin antagonists
US20080234252A1 (en) 2005-05-18 2008-09-25 Pfizer Inc Compounds Useful in Therapy
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102010041236A1 (de) * 2010-09-23 2012-03-29 Osram Ag Optoelektronisches Halbleiterbauelement
DE102010044131A1 (de) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat

Also Published As

Publication number Publication date
ES2641205T3 (es) 2017-11-08
LT2847183T (lt) 2017-09-25
CA2872726A1 (en) 2013-11-14
PE20142453A1 (es) 2015-01-17
MY184577A (en) 2021-04-06
UA116349C2 (uk) 2018-03-12
BR112014027564B1 (pt) 2022-05-03
CA2872726C (en) 2020-07-07
CN104411704B (zh) 2017-12-22
JP6149104B2 (ja) 2017-06-14
CN104411704A (zh) 2015-03-11
PH12014502482A1 (en) 2015-01-12
EA201492032A1 (ru) 2015-04-30
NZ701661A (en) 2016-08-26
AP2014008089A0 (en) 2014-11-30
US10301289B2 (en) 2019-05-28
JP2015516403A (ja) 2015-06-11
MX2014013448A (es) 2014-12-08
PT2847183T (pt) 2017-10-02
KR102086389B1 (ko) 2020-03-09
HUE034430T2 (en) 2018-02-28
HK1208027A1 (en) 2016-02-19
IL235441A (en) 2017-09-28
AU2013258107A1 (en) 2014-11-27
SG10201609319YA (en) 2016-12-29
KR20150018534A (ko) 2015-02-23
SI2847183T1 (sl) 2017-10-30
CL2016001165A1 (es) 2016-12-02
BR112014027564A2 (es) 2017-08-22
TN2014000469A1 (en) 2016-03-30
WO2013167552A1 (de) 2013-11-14
DOP2014000254A (es) 2016-01-31
EP2847183B1 (de) 2017-06-21
ZA201408571B (en) 2016-03-30
EA027804B1 (ru) 2017-09-29
AU2013258107B2 (en) 2017-06-22
DK2847183T3 (en) 2017-10-02
PL2847183T3 (pl) 2017-11-30
CO7121324A2 (es) 2014-11-20
EP2847183A1 (de) 2015-03-18
RS56255B1 (sr) 2017-11-30
HRP20171321T1 (hr) 2017-10-20
CU20140128A7 (es) 2015-03-30
CL2014003003A1 (es) 2015-02-13
SG11201407043PA (en) 2014-12-30
MX350519B (es) 2017-09-08
US20150087827A1 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
CR20140514A (es) Proceso preparativo
UY34260A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-etoxi-etil}-1h-[1,2,4]triazol sustituidos
UY34257A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alquiniloxi-etil}-1h-[1,2,4]triazol sustituidos
UY34259A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-3-metil-butil}-1h-[1,2,4]triazol sustituidos
UY34261A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-2-ciclil-etil}-1h-[1,2,4]triazol sustituidos
UY34258A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-2-alquinil/alquenil-etil}-1h-[1,2,4]triazol sustituidos
SA113340696B1 (ar) تصنيع 2-(5-برومو-4-(4-سيكلو بروبيل نافثالين-1-يل)-4 h-1، 2، 4- ترازول-3- يل ثيو) حمض أسيتيك
TN2012000347A1 (en) 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
MA33835B1 (fr) Sels de 4-[2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine
UA111725C2 (uk) Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол
ECSP13012627A (es) 1h-pirazol-5-olato sódico sustituido
BR112014009308A2 (pt) formas de dosagem sólida de 2-amino-3-(4-(2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifloroetóxi) pirimidin-4-il)fenil) propanoato de (s)-etila
CL2014001247A1 (es) Forma de dosificacion solida de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida; metodo de preparacion.
IL244933A0 (en) Pharmaceutical dosage forms containing sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(3,2,1-1h-triazol-1-yl)-1h-pyrazol-5-olate
TH152857A (th) วิธีการสำหรับการเตรียมของสารประกอบไตรอาซอล
NZ623098A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
TH148782B (th) รูปแบบปริมาณขนาดยาชนิดแข็งที่ให้ของ (S)-เอทธิล-2-อะมิโน-3-(4-(2-อะมิโน-6-((R)-1-(4-คลอโร-2-(3-เมทธิล-1H-ไพราซอล-1-อิล)ฟีนิล)-2,2,2-ไตรฟลูออโรเอทธอกซี) ไพริมิดิน-4-อิล)ฟีนิล)โพรพาโนเอต ((S)-ethyl-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-y1)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate)
TR201105728A2 (tr) 2-(2,4-diflorofenil)-1,3-bis(1h-1,2,4-triazol-1-il)propan-2 ol'ün farmasotik bir bileşim içerisinde kullanımı.
TH134802B (th) 5-(เฟนิล/ไพริดินิล-เอไธนิล)-2-ไพริดีน/2-ไพริมิดีน-คาร์บอกซาไมด์ ในรูปตัวคุม mglur5